SANOFI PASTEUR INC.

Systems and methods can apply machine learning techniques to predict biological responses. One of the methods is performed by at least one processor executing executable logic including at least one machine learning model trained to predict biological responses. The method includes receiving first sequence data of a first molecular sequence, receiving second sequence data of a second molecular sequence, and predicting a biological response for the second molecular sequence based at least partly on the received first and second sequence data.

Disclosed herein are cell-free protein synthesis systems, reaction mixtures for the same, and methods for preparing a protein of interest.

The present invention provides a method for monitoring an in vitro transcription (IVT) reaction for the production of RNA within a reaction vessel. The method comprises obtaining a spectrum of a reactant or product during the IVT reaction and comparing the obtained spectrum to a pre-determined reference spectrum of the reactant or product of the IVT reaction. The method can be used to determine changes in the amount of the reactant or product during the IVT reaction.

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid (TT) or CRM 197 , wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM 197 . Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject.

Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.

Systems and methods can apply machine learning techniques to predict biological responses. One of the methods is performed by at least one processor executing executable logic including at least one machine learning model trained to predict biological responses. The method includes receiving first sequence data of a first molecular sequence, receiving second sequence data of a second molecular sequence, and predicting a biological response for the second molecular sequence based at least partly on the received first and second sequence data.

The disclosure relates to an immunogenic composition comprising a combination of Neisseria meningitidis serogroup B antigens, said combination comprising at least one factor H binding protein (fHBP) A and at least one factor H binding protein (fHBP) B, and an aluminum hydroxyphosphate (AlPO 4 ) adjuvant, the AlPO 4 adjuvant being selected as having a point of zero charge (PZC) below 5.

Provided herein is a messenger RNA (mRNA) comprising, from 5′ to 3′, a 5′ untranslated region (5′ UTR), at least one open reading frame (ORF), a 3′ untranslated region (3′ UTR), and a GC-rich sequence, wherein the mRNA comprises at least one chemical modification. Also provided are methods of producing a plurality of chemically modified mRNA molecules with polyA sequence lengths of at least about 200 consecutive adenosine nucleotides.

The present disclosure relates to a cluster-based consensus approach for generating recombinant neuraminidase (NA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant NA polypeptides.

The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exetpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.